1名受试者出现肝损伤,辉瑞终止一款口服减肥药临床开发,死磕小分子GLP-1

时代财经
15 Apr

一款口服减重药折戟。图片来源:图虫创意跨国药企辉瑞(PFE.US)又终止一款口服GLP-1R激动剂的临床开发。时代财经从辉瑞获悉,美国时间4月14日,辉瑞宣布决定终止开发每日一次的口服GLP-1R(口服胰高血糖样肽-1)激动剂Danuglipron(PF-06882961),该药物用于减重管理。由于安全性问题待解,辉瑞经多方考虑后选择终止开发这一小分子药物。辉瑞对外公布了Danuglipron转向...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10